Advertisement

Topics

Pfizer Enters Feasibility Study Agreement Evaluating Alcyone’s Pulsar Technology for Use in Gene Therapy Targeting CNS Disorders

12:11 EDT 29 Jun 2017 | Speciality Pharma Journal

LOWELL, Mass., June 29, 2017 /PRNewswire/ — Alcyone Lifesciences, Inc., a leader in precision advanced central nervous system (CNS) delivery systems announced that it has entered into a feasibility study agreement with Pfizer Inc. (NYSE: PFE) in the area of genetic therapy targeting rare and orphan neurological disorders. The feasibility study combines Alcyone’s proprietary PulsarTM …

Original Article: Pfizer Enters Feasibility Study Agreement Evaluating Alcyone’s Pulsar Technology for Use in Gene Therapy Targeting CNS Disorders

NEXT ARTICLE

More From BioPortfolio on "Pfizer Enters Feasibility Study Agreement Evaluating Alcyone’s Pulsar Technology for Use in Gene Therapy Targeting CNS Disorders"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...